Neomorph, Inc. to Participate in Upcoming Guggenheim Healthcare Talks – Targeted Protein Degradation Day
SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a rapidly growing biotechnology company comprised of industry leading experts in the field of targeted protein degradation (TPD), today announced that it will participate in an upcoming virtual investor conference:
Guggenheim Healthcare Talks - Targeted Protein Degradation Day: Fireside chat led by Phil Chamberlain, D.Phil., Co-Founder, President, & Chief Executive Officer on Wednesday, March 16, 2022, at 3:30pm ET.
Presentation webcasts will be available in the News section of Neomorph’s website https://neomorph.com/index.html#news.
Neomorph is a venture backed biotechnology company solving critical problems in human health by discovering innovative new medicines against ‘undruggable’ targets. Our team is comprised of industry leading experts in protein degradation and molecular glues who have a track record of ground-breaking discoveries in the field. We are committed to leadership in advancing the science and technology of molecular glue drug discovery, while prosecuting a pipeline of projects through clinical development. Our patient-first, science-driven approach is complemented by our dedication to a supportive and collaborative work environment. Neomorph is headquartered in San Diego, California, and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute.
Investor Contact: Marla Bornstein, firstname.lastname@example.org
Media Contact: email@example.com